Are analysts optimistic about SLNO's EPS turnaround?

**Analysts are optimistic about SLNO's EPS turnaround**, as evidenced by the following points: 1. **Increased Price Target**: Oppenheimer recently lifted the price target for Soleno Therapeutics Inc. (NASDAQ: SLNO) shares to $105, up from $73. This increase reflects a more positive outlook on the stock and suggests that analysts believe the company's earnings potential is improving. 2. **Positive Earnings Forecast**: Analysts forecast a positive EPS of $7.31 for FY2025. This projection indicates a significant improvement from the current EPS, suggesting that analysts are optimistic about the company's ability to generate earnings in the near future. 3. **Strong Institutional Interest**: Institutional investors have shown significant interest in Soleno Therapeutics, with many increasing their holdings in the company. This strong institutional support can be a bullish signal, as it indicates that these investors believe in the company's potential for growth and profitability. 4. **Potential for Peak Sales**: The FDA approval of Vykat XR for the treatment of hyperphagia in Prader-Willi syndrome has led to an upward revision in the sales forecast, with peak sales potential in the United States now estimated to reach $2 billion. This significant increase from the previous estimate of $1.5 billion reflects analysts' optimism about the drug's market potential and the company's ability to capitalize on it. 5. **Consensus Rating**: The consensus rating for Soleno Therapeutics is "Strong Buy," with price targets ranging from $70 to $123. This indicates that analysts are generally optimistic about the stock's future performance and believe it has the potential for further price appreciation. In conclusion, the combination of the increased price target, positive earnings forecast, strong institutional interest, potential for peak sales, and consensus rating all point to a positive outlook on SLNO's EPS turnaround. Analysts are indeed optimistic about the company's future earnings potential.